The final price depends on dose, location, pharmacy discounts, and available savings programs
The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists, or GLP-1s, at $200 and counts the spending toward annual deductibles, the company announced in a news release today
Monitor for Reactions:Keep an eye on how your skin responds to the product
The removal of water during the lyophilization process dramatically slows the chemical degradation pathways that affect liquid formulations
FDAs concerns with unapproved GLP-1 drugs used for weight loss, United States Food and Drug Administration (2024) FDA approves first oral GLP-1 treatment for Type 2 diabetes, United States Food and Drug Administration (2019) Semaglutide for Type 2 diabetes, CADTH Health Technology Review (2023) Anti-inflammatory benefits of semaglutide: State of the art, Journal of Clinical & Translational Endocrinology (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Creates a more natural-looking tan: Helps reduce patchiness and uneven tones, leading to smoother, more uniform skin coloration